Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 3Recruiting 1Completed 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5Genitourinary 2Thoracic 1

Conditions

Pancreatic Neoplasms 2Stomach Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Bile Duct Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Oxaliplatin 1413Fluorouracil 1301Capecitabine 1087Gemcitabine 1045Leucovorin 932Irinotecan 818Bevacizumab 804Cisplatin 669Radiotherapy 536Cetuximab 470pembrolizumab 428Paclitaxel 390Nivolumab 337130-nm albumin-bound paclitaxel 325Drug Therapy 314Docetaxel 287S 1 (combination) 274Sorafenib 266Folfox protocol 261Albumin-Bound Paclitaxel 259sintilimab 211durvalumab 210Surgical Procedures, Operative 204tislelizumab 203Radiosurgery 202lenvatinib 201apatinib 200Carboplatin 187Magnetic Resonance Spectroscopy 183regorafenib 181

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × quemliclustat × Gastrointestinal × Clear all
NCT04104672 2026-06-02

ARC-8

Arcus Biosciences, Inc.

Phase 1 Active not recruiting
196 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT05329766 2026-06-02

EDGE-Gastric

Arcus Biosciences, Inc.

Phase 2 Active not recruiting
332 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT06608927 2026-06-02

PRISM-1

Arcus Biosciences, Inc.

Phase 3 Active not recruiting
610 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT06048133 2026-01-23

Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)

Big Ten Cancer Research Consortium

Phase 2 Recruiting
33 enrolled
Gastrointestinal

Bile Duct Neoplasms, Cholangiocarcinoma

NCT04660812 2025-10-20

ARC-9

Arcus Biosciences, Inc.

Phase 1/2 Completed
227 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡